Targeting the immune environment in anaplastic thyroid cancer
Targeting immune suppressive microenvironment in ATC
This study is looking for better ways to help people with anaplastic thyroid cancer by using new treatments that boost the immune system to fight the cancer more effectively, and patients may have the chance to try these exciting new options in clinical trials.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11010842 on NIH RePORTER |
What this research studies
This research investigates how to improve treatment outcomes for patients with anaplastic thyroid cancer (ATC) by targeting the immune suppressive microenvironment that hinders effective therapy. The approach involves using a combination of targeted therapies that inhibit specific pathways in cancer cells, aiming to enhance the immune response against the tumor. By studying the interactions between tumor-associated macrophages and T cells in ATC, the research seeks to identify new strategies to overcome resistance to existing treatments. Patients may be involved in trials that explore these innovative treatment combinations.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with anaplastic thyroid cancer, particularly those with BRAF mutations.
Not a fit: Patients with other types of thyroid cancer or those without BRAF mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options and improved survival rates for patients with anaplastic thyroid cancer.
How similar studies have performed: Other research has shown promising results with similar approaches in targeting immune suppression in various cancers, indicating potential for success in this area as well.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Fagin, James a — Sloan-Kettering Inst Can Research
- Study coordinator: Fagin, James a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.